Literature DB >> 14614206

Case report: patient with multiple paragangliomas treated with long acting somatostatin analogue.

Vedia Tonyukuk1, Rifat Emral, Sule Temizkan, Ayşe Sertçelik, Ilhan Erden, Demet Corapçioğlu.   

Abstract

Paragangliomas of the head and neck are uncommon neoplasms. They are usually benign, but tend to be locally invasive. Although surgical resection remains the definitive treatment, important issues about management arise when such lesions are inoperable. Beneficial effects of octreotide treatment have already been reported in a malign paraganglioma case. Here we report a 24 year old female with familial, bilateral, multiple paraganglioma in the head and neck region, who firstly presented with pulsatile tinnitus and hearing loss in her left ear. After embolization was performed, she underwent operation twice because of the gross tumor mass. No significant change in tumor size was determined after the operations, however there were no distant metastases. Although she experienced hypertension attacks, no hormonal overproduction was found in repeated measurements. As the tumor was unresectable, new alternative therapies were sought. Octreotide scintigraphy was positive in the tumoral tissue, so we began to treat her with somatostatin analogue octreotide. After a 16 month follow up period, an improvement of the performance status, the near normalisation of attacks and stabilization of tumor growth were achieved. However, in the last three visits, she began to experience symptoms more frequently and it had been necessary to increase the octreotide dose. She is now well and being followed up. In conclusion, the beneficial effects of octreotide treatment could be quantified by clinical, tumor and scintigraphic criteria. These data suggest that octreotide can be useful in the treatment of inoperable paragangliomas.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14614206     DOI: 10.1507/endocrj.50.507

Source DB:  PubMed          Journal:  Endocr J        ISSN: 0918-8959            Impact factor:   2.349


  6 in total

1.  Non-functional paraganglioma of retroperitoneum mimicking pancreatic mass with concurrent urinary bladder paraganglioma: an extremely rare entity.

Authors:  Ankur Verma; Diwakar Pandey; Azaz Akhtar; Ashish Arsia; Nain Singh
Journal:  J Clin Diagn Res       Date:  2015-02-01

2.  Role of 68Ga-DOTATATE PET/CT in a Case of SDHB-Related Pterygopalatine Fossa Paraganglioma Successfully Controlled with Octreotide.

Authors:  Abhishek Jha; Mayank Patel; Eva Baker; Melissa K Gonzales; Alexander Ling; Corina Millo; Marianne Knue; Ali Cahid Civelek; Karel Pacak
Journal:  Nucl Med Mol Imaging       Date:  2020-01-22

Review 3.  Primary retroperitoneal paraganglioma simulating a pancreatic mass: a case report and review of the literature.

Authors:  Guillermo Sangster; Daniel Do; Carlos Previgliano; Benjamin Li; Delecia LaFrance; Maureen Heldmann
Journal:  HPB Surg       Date:  2010-12-06

4.  Evaluation of somatostatin, CXCR4 chemokine and endothelin A receptor expression in a large set of paragangliomas.

Authors:  Daniel Kaemmerer; Jörg Sänger; Ruza Arsenic; Jan G D'Haese; Jens Neumann; Annette Schmitt-Graeff; Ralph Markus Wirtz; Stefan Schulz; Amelie Lupp
Journal:  Oncotarget       Date:  2017-09-23

5.  Functional extra-adrenal paraganglioma of the retroperitoneum giving thoracolumbar spine metastases after a five-year disease-free follow-up: a rare malignant condition with challenging management.

Authors:  Stylianos Kapetanakis; Danai Chourmouzi; Grigorios Gkasdaris; Vasileios Katsaridis; Eleftherios Eleftheriadis; Panagiotis Givissis
Journal:  Pan Afr Med J       Date:  2017-09-29

Review 6.  Somatostatin Receptors and Analogs in Pheochromocytoma and Paraganglioma: Old Players in a New Precision Medicine World.

Authors:  Mayank Patel; Isabel Tena; Abhishek Jha; David Taieb; Karel Pacak
Journal:  Front Endocrinol (Lausanne)       Date:  2021-03-29       Impact factor: 5.555

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.